Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Running heads: Recto: Hypersensitivity reaction with SARS-CoV-2 vaccine Verso: D. Savva et al.

Hypersensitivity reaction to hyaluronic acid dermal filler after the Pfizer vaccination against SARS-CoV-2

Demetris Savva\textsuperscript{a}, Gopi Battineni\textsuperscript{b}, Francesco Amenta\textsuperscript{b}, Giulio Nittari\textsuperscript{b,\ast}

\textsuperscript{a}Plastic Reconstructive and Aesthetic Surgery, Nicosia General Hospital, Nicosia, Cyprus.
\textsuperscript{b}Telemedicine and Telepharmacy Centre, School of Medicinal and Health Products Sciences, University of Camerino, Camerino, 62032, Italy

1. Introduction

The novel coronavirus (2019-nCoV), named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected approximately 250 million people worldwide killed more than 3.7 million individuals (\textit{n.d.}). The rapid spreading of the pandemia has stimulated the implementation of numerous measures to combat the spread of the virus, such as closures of geographical areas, lockdowns, restrictions on the circulation of citizens and closure of various types of activities and businesses (\textit{Galanakis, 2020}). The development of several effective vaccines against the virus has given new energy to the fight against Covid. The availability of vaccines has allowed the launch of vaccination campaigns that are reducing the spread of infection and countering the complications caused by the disease among the most vulnerable sections of the population (\textit{Shrotri et al., 2021}). From the starting of vaccination campaigns by December 2020, it is estimated that 49.7\% of the world population has received at least one dose of a COVID-19 vaccine, 7.13 billion doses have been administered globally, and 27.81 million are now administered each day. Unfortunately, only 3.9\% of people in low-income countries have received at least one dose of vaccine. Despite the undoubted advantages of vaccination against Covid, the vaccine may induce adverse reactions or even serious side effects in particular patients. The practices of aesthetic medicine are to be considered with some attention in subjects that must be vaccinated or have been vaccinated against the Covid close to medical-aesthetic treatment. The possible interactions and adverse reactions caused by Covid-19 vaccines in aesthetic medicine practice have been discussed. Some scientific societies have issued guidelines or recommendations for aesthetic medicine treatments. The main attention was concentrated to aesthetic fillers in conjunction with administration of Covid vaccines (\textit{Arora et al., 2020; Gotkin et al., 2021}). In this case report, we present a hypersensitivity reaction to hyaluronic acid dermal filler in a subject being vaccinated against the SARS-CoV-2 virus.

2. Case presentation

A 38-year-old female patient with no known allergies, who had previously been treated with hyaluronic acid fillers in the lips, had an adverse reaction following a booster shot vaccination with the COVID-19 Pfizer-BioNTech vaccine. The hyaluronic acid injections had been done on the December 11, 2020. Using a 0.4 ml solution of hyaluronic acid 25 mg/ml using a 27G needle. The needle was placed according to a linear technique on the vermilion border of the upper and lower lip. A 0.6 ml amount of hyaluronic acid was used for a volumizing effect. The patient under went her first vaccine dose on January 8, 2021. After vaccination a mild reaction to the dermal filler that subsided by itself occurred. Small erythema-
tous nodules were visible on both the upper and lower lip with mild pain were visible from day 2 post-vaccine. These nodules dis-appeared completely in 7 days with no medical intervention. On February 11, 2021 the patient proceeded with her second dose of the Pfizer vaccine. On April 13, 2021 the patient complained a mild tenderness on her upper lip and two days later a painful erythematous oedema was developed on both the upper and lower lip (Figure 1).

After the development of these lesions, the patient was care-fully checked and her medical history established that she did not suffered from any infection or trauma in the area, no dental inci-dent occurred, no new medicines were administrated, and no med-i-cal procedures took place between the filler injection and the lo-cal swelling. No extra-site symptoms were noted, except the local-ized pain and erythematous oedema on her lips. A diagnosis of a delayed-type hypersensitivity reaction to hyaluronic acid der-mal fillers after SARS-CoV-2 vaccination was consequently made. The patient was treated with methylprednisolone tablets (Day 1&2: 6mg, Day 3-5: 4mg, Day 6-8: 2mg). In 5 days an obvious improve-ment characterized by a reductions in the swelling and the pain was noticeable (Figure 2).

3. Discussion

The use of dermal fillers has an increasing demand and popu-larity in the last few years in aesthetic medicine. Hyaluronic acid fillers are preferencing for people seeking a quick, temporary, and non-invasive procedure with minimal side effects. Dermal fillers have a very low risk profile, with side effects that include local and transient bruising and oedema. They are non-allergenic, non-carcinogenic, and generally represent a stable and cost-effective choice for the patient.

Hypersensitivity reactions can be easily classified into acute and delayed. Acute or type I hypersensitivity reactions have an onset within minutes to hours from injection time and they are immunoglobulin-E, mediated. They resulted in an anaphylactic reaction often presented as angioedema (Arron and Neuhau, 2007). The mechanism of action of the delayed-type hypersensitivity reac-tion to dermal fillers is not yet clear, but is more likely to be mul-tifactorial. Various aetiological factors have been suggested, includ-ing filler properties (cross-linking, rheology, etc.), injection tech-nique (quantity, repeated injections, needle placement instead of cannula, intramuscular placement, etc.), and previous trauma or in-fection in the area of injection (Polack et al., 2020).

Delayed or type IV hypersensitivity reactions can take place from 24 hours to months after allergen contact. Delayed-type hy-persensitivity reaction to dermal fillers is a very rare complica-tion that usually presents as a tender, erythematous swelling. It is a cell-mediated hypersensitivity reaction caused by T-lymphocytes (Marshall et al., 2018). Delayed hypersensitivity reactions of type IV with dermal fillers aetiology is not yet fully understood. Various factors including filler properties (cross-linking, rheology, etc.), in-jection technique (quantity, repeated injections, needle placement instead of cannula, intramuscular placement, etc.), and previous trauma or infection in the area of injection have shown a cor-relation with this type of hypersensitivity reaction post-injection (Marshall et al., 2018; Turkmani et al., 2019a). It is worth mention-ing that various case reports of delayed hypersensitivity reactions to dermal fillers after influenza-type illnesses have been published (Rowland-Warmann, 2021; (Turkmani et al., 2019b)).

Five cases of a delayed-type hypersensitivity reaction to dermal fillers, with influenza-like symptoms occurring a couple of days before the onset of inflammation were reported (Bhojani-Lynch, 2017). Oral corticosteroids were used to treat the inflammation and hyaluronidase to suppress the persistent areas. Another 14 cases of delayed-type hypersensitivity reactions to fillers have been re-ported following an influenza-like illness (Turkmani et al., 2019a). Almost all cases were treated with oral corticosteroids, whereas a few persistent nodules needed intralesional hyaluronidase in-jections to be dissolved completely. There is no evidence of de-layed hypersensitivity with hyaluronic acid fillers following in-fluenza vaccination.

Clinical trials on COVID vaccines (Pfizer-BioNTech, Moderna, and AstraZeneca) have reported some cutaneous adverse reactions (Baden et al., 2021; Jackson et al., 2020; Mulligan et al., 2020; Ramasamy et al., 2020; Walsh et al., 2020). Rosacea and pruritus occurred in the AstraZeneca vaccine trials, whereas transient ur-ticaria and a case of angioedema were noted in the Moderna vac-cine trial. It is important to note that no cases of delayed type hypersensitivity reactions are noted for the AstraZeneca or Pfizer vaccine. We can concluded that they either did not take place or the number of cases did not meet the minimum threshold incident value for the protocol for reporting adverse effects. Various cases of delayed-type hypersensitivity reactions related to viral vaccines and illnesses are reported.

The exact mechanism of triggering a delayed-type hypersensi-tivity reaction in our case needs be clarified, but the most proba-ble hypothesis is the occurrence of an immunological reaction be-tween the hyaluronic acid filler and the SARS-CoV-2 vaccine. Gen-erally, hyaluronic acid fillers are very safe to use and only minimal side effects can occur. The aesthetic practitioner must be aware of those potential side effects, and precautions before and after use of these fillers as well the contraindications of using hyaluronic acid fillers should be taken into account. In view of the possibility of being more prone to possible filler side effects in concomitance with a Covid vaccination, informed consents should include spe-cific information about the possible side effects after influenza-like illnesses/vaccination and nowadays after Covid-19 infection and/ or after Covid 19 vaccination. The American Society of Dermato-logic Surgery (ASDS) has issued a guidance report on SARS-CoV-2 vaccine-related adverse effects, and in particular on delayed der-mal filler inflammatory reactions (American Society for Derma-tological Surgery, 2021). An adequate patient’s information about these rare but possible adverse reactions before proceeding with the treatment is therefore necessary. Another important point is to inform patients treated with hyaluronic acid filler injections be-fore their vaccination, about the rare possibility of a delayed-type hypersensitivity reaction, as part of the post-vaccination adverse effects.
Funding

This work did not receive any source of funding.

Ethical approval

Written informed consent for publication of the clinical details and images was obtained from the patient.

Conflict of interest

The authors declare no financial or other competing interests associated with this work [Au?2].

References

American Society for Dermatological Surgery, 2021; retrieved from https://www.plasticsurgery.org/for-medical-professionals/covid19-member-resources/covid-19-vaccine-dermal-fillers

Arora G, Arora S, Talathi A, Kandhari R, Joshi V, Langar S, et al. Practice of Aesthetic Dermatology during the COVID-19 Pandemic: Recommendations by SIG Aesthetics (IADVL Academy). Indian Dermatol Online J 2020;11(4):534–9. doi:10.4103/idoj.IDOJ_328_20.

Arron ST, Neuhaus RM. Persistent delayed-type hypersensitivity reaction to injectable non-animal-stabilized hyaluronic acid. Journal of Cosmetic Dermatology 2007;6(3):167–71. doi:10.1111/j.1473-2165.2007.00331.x.

Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Specor SA, Rouphael N, Creech CB, McGgettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, ... Zaks S, Voysey M, Aley PK, Angus B, Babbage G, Belij-Rammerstorfer S, Berry L, Bibi S, Bittaye M, Cathie K, Chappell H, Charlton S, Cicconi P, Clutterbuck EA, ... Zizi D. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV022): a single-blind, randomised, controlled, phase 2/3 trial. The Lancet 2020;396(10267):1979–93. doi:10.1016/S0140-6736(20)32466-1.

Bhandari-Lynch T. Late-onset inflammatory response to hyaluronic acid dermal fillers. Plastic and Reconstructive Surgery - Global Open 2017;5(12). doi:10.1097/GOX.00000000000001532.

Galaniaki CM. The food systems in the era of the coronavirus (CoVid-19) pandemic crisis. MDPI Multidisciplinary Digital Publishing Institute; 2020 In Foods (Vol. 9, Issue 4, p. 523).

Home - Johns Hopkins Coronavirus Resource Center. (n.d.). 2021 Retrieved November 4, 2021, from https://coronavirus.jhu.edu

Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruissers AJ, McDermott A, Flach B, Doria-Rose NA, Corbett KS, Morabito KM, O’Dell S, Schmidt SD, Swanson PA, ... Beigel JH. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. New England Journal of Medicine 2020;383(20):1920–31. doi:10.1056/nejmoa2022483.

Marshall JS, Warrington R, Watson W, Kim HL. An introduction to immunology and immunopathology. In Allergy, Asthma and Clinical Immunology (Vol. 2018;14 Issue Suppl 2)BioMed Central Ltd., doi:10.1186/s13232-018-0278-1.

Mulligan MJ, Lyke KE, Kitchin N, Ahsalon J, Guttman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fortes-Garclaus C, Shi PY, Türeci O, Tompkins KR, Walsh EE, ... Jensen KU. Phase II/I study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020;586(7830):589–93. doi:10.1038/s41586-020-2639-4.

Polack FP, Thomas SJ, Kitchin N, Ahsalon J, Guttman A, Lockhart S, Perez JI, Marc Perez, Moreira G, E D, Zerec T, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW, Hammitt LT, Gruber ..., W C. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine 2020;383(27):2603–15. doi:10.1056/nejmoa2034577.

Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens B, Voysey M, Aley PK, Angus B, Babbage G, Belij-Rammerstorfer S, Berry L, Bibi S, Bittaye M, Cathie K, Chappell H, Charlton S, Cicconi P, Clutterbuck EA, ... Zizi D. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV022): a single-blind, randomised, controlled, phase 2/3 trial. The Lancet 2020;396(10267):1979–93. doi:10.1016/S0140-6736(20)32466-1.

Rowland-Warrmann M. Hypersensitivity reaction to Hyaluronic Acid Dermal filler following novel Coronavirus infection – a case report. Journal of Cosmetic Dermatology 2021;20(5):1557–62. doi:10.1111/jocd.14074.

Shrotri M, Swinnen T, Kampmann B, Parker EPK. An interactive website tracking COVID-19 vaccine development. Elsevier Ltd., 2021. p. e580–2.

Turkmani MC, Bourle K, Philipp-Dormston W. Delayed hypersensitivity reaction to hyaluronic acid dermal filler following influenza-like illness. Clinical, Cosmetic and Investigational Dermatology, 2019;12:277–83. doi:10.2147/CCID.S190081.

Turkmani MC, Bourle K, Philipp-Dormston W. Delayed hypersensitivity reaction to hyaluronic acid dermal filler following influenza-like illness. Clinical, Cosmetic and Investigational Dermatology, 2019;12:277–83. doi:10.2147/CCID.S190081.

Walsh EE, Frenck RW, Faliery AR, Kitchin N, Ahsalon J, Guttman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fortes-Garclaus C, Shi PY, Türeci O, Tompkins KR, ... Gruber WC. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. New England Journal of Medicine 2020;383(25):2439–50. doi:10.1056/nejmoa2034577.

Gotkin RH, Gout U, Sattler S, Piansay-Soriain ME, Wanitphakdeechoke R, Ghanam N, et al. Global Recommendations on COVID-19 Vaccines and Soft Tissue Filler Reactions: A Survey-Based Investigation in Cooperation With the International Society for Dermatologic and Aesthetic Surgery (ISDS). J Drugs Dermatol 2021;20(4):374–8. doi:10.36849/JDD.2021.6041.